Clik here to view.
Alpha Holdings Provides Update on Opposition to OncoSec Takeover Proposal
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec” or the “Company”), with an...
View ArticleClik here to view.
AVITA Medical Names David McIntyre as Chief Financial Officer
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
ITM and CIRC Sign Technology License Agreement for the Production and...
MUNICH & GARCHING, Germany ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and Chengdu Gaotong Isotope Co., Ltd. a subsidiary of China...
View ArticleClik here to view.
Kraig Biocraft Laboratories Completes Scale-Up Production Cycle of...
ANN ARBOR, Mich. Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that Prodigy Textiles, the Company’s Vietnamese...
View ArticleClik here to view.
Wellington Management Announces Close of Biomedical Innovation Fund I at $393M
BOSTON & HONG KONG & LONDON Wellington Management (“Wellington” or the “Firm”), one of the world’s largest independent investment management firms, today announced the final close of the...
View ArticleClik here to view.
Propanc Biopharma Advances POP1 Drug Discovery Program
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
QIAGEN收到若干附条件无约束力收购意向，决定进入探索潜在战略替代方案的讨论
荷兰芬洛 (美国商业资讯)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) （简称“QIAGEN”或“公司”）宣布，在收到关于收购公司所有已发行流通股的若干附条件无约束力意向后，其已开始审核潜在战略替代方案。...
View ArticleClik here to view.
キアゲン、条件付きの拘束力のない関心表明を数件受領し、可能な戦略的代替案を検討するために協議を開始することを決定
蘭フェンロー （ビジネスワイヤ） — キアゲンNV（NYSE：QGEN、フランクフルト・プライムスタンダード：QIA）は、当社の全発行済み流通株式の取得について、条件付きで拘束力のない関心表明を数件受領し、可能な戦略的代替案の検討を開始したと発表しました。...
View ArticleClik here to view.
FDA Accepts Samsung Bioepis’ BLA for SB8 Bevacizumab Biosimilar Candidate
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k)...
View ArticleClik here to view.
Clinical Innovations聘请Rebecca Liu刘旼为全球副总裁兼CI Medical...
盐湖城 (美国商业资讯)–专注于分娩和新生儿重症监护的全球最大医疗器械公司之一Clinical Innovations今天宣布，其已聘请Rebecca Liu刘旼为全球副总裁兼CI Medical Instruments禧暧医疗器械（上海）有限公司大中华区总经理。 刘女士是一位经验丰富的高管，她曾推动多家美国医疗保健公司在中国实现两位数增长。她的聘用标志着Clinical...
View ArticleClik here to view.
Clinical Innovations hires Rebecca Liu as VP, general manager for CI Medical...
SALT LAKE CITY Clinical Innovations, one of the world’s largest medical device companies focused on labor and delivery and neonatal intensive care, announced today that it has hired Rebecca Liu as...
View ArticleClik here to view.
EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Mevion Signs Agreement to Bring Proton Therapy to Central Taiwan
LITTLETON, Mass. Mevion Medical Systems today announced it had signed a collaborative framework agreement with Chung Shan Medical University Hospital and ASYS Corp to provide advanced proton therapy...
View ArticleClik here to view.
路胜生物完成由IHH Healthcare领投的2千万美元A轮投资，用于推动液体活检技术，进行多种癌症早期检测
新加坡 (美国商业资讯)– 路胜生物(Lucence)，发明用于癌症筛查, 治疗选择的血液检测的基因组医学公司，今天宣布完成2千万美元A轮融资。此轮融资的领投者是全球最大的综合私人医疗保健集团之一IHH Healthcare。参投者包括新加坡创新机构(SGInnovate)，以及现有投资者淡马锡控股(Temasek Holdings) 旗下的海丽凯资本管理公司(Heliconia...
View ArticleClik here to view.
Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid...
SINGAPORE Lucence, a genomic medicine company that invents blood-based tests for cancer screening and treatment selection, announced today the close of USD $20 million in Series A funding. The round...
View ArticleClik here to view.
注意-更正并替换: Clinical Innovations聘请Rebecca Liu刘旼为全球副总裁兼CI Medical...
盐湖城 (美国商业资讯)–专注于分娩和新生儿重症监护的全球最大医疗器械公司之一Clinical Innovations今天宣布，其已聘请Rebecca Liu刘旼为全球副总裁兼CI Medical Instruments禧暧医疗器械（上海）有限公司大中华区总经理。 刘女士是一位经验丰富的高管，她曾推动多家美国医疗保健公司在中国实现两位数增长。她的聘用标志着Clinical...
View ArticleClik here to view.
Clik here to view.
Freyr Unveils a Pathbreaking Regulatory Labeling Platform – Freyr LABEL 360
NEW JERSEY Freyr Solutions, a leading Regulatory solutions and services provider, has unveiled a pathbreaking labeling platform – Freyr LABEL 360. Touted to be a single-stop labeling solution, Freyr...
View ArticleClik here to view.
PanTheryx宣布，APS BioGroup与VitaDairy签署妇幼免疫营养领域价值数百万美元的排他性协议
科罗拉多州博尔德 (美国商业资讯)–PanTheryx是一家致力于实现基于牛初乳治疗药物潜力的生物技术公司，公司今天宣布，其全资子公司APS BioGroup与领先的越南营养乳品公司VitaDairy签署一份价值数百万美元的协议。该协议的签署标志着VitaDairy、成长奶市场和越南儿童健康的转折点。 按此三年期协议，APS BioGroup成为VitaDairy的Colos IgG...
View ArticleClik here to view.
三叶草生物制药在研1类新药SCB-313在澳洲开展的恶性胸水I期临床完成首例患者给药
成都 三叶草生物制药，一家全球临床阶段，致力于创新及变革性生物制药研发的生物制药公司，今天宣布在澳洲进行的另一项SCB-313 I期临床试验完成首例患者给药。SCB-313是一种创新重组人肿瘤坏死因子相关凋亡诱导配体（TRAIL）-...
View Article